GSK: positive data for HIV therapy
(CercleFinance.com) - On Monday ViiV Healthcare, a subsidiary of GSK, released new positive Phase III data on experimental HIV treatment injected once every two months.
According to the results of a study conducted over a period of 48 weeks, the dual therapy, combining ViiV's cabotegravir with Janssen's rilpivirine has proven to be as effective when taken once every two months as when taken monthly.
Kimberly Smith, head of research and development at ViiV Healthcare, points out that this treatment - which is not yet marketed - has the advantage, for HIV positive patients, of limiting the use of drugs to six times per year, against 365 today.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the results of a study conducted over a period of 48 weeks, the dual therapy, combining ViiV's cabotegravir with Janssen's rilpivirine has proven to be as effective when taken once every two months as when taken monthly.
Kimberly Smith, head of research and development at ViiV Healthcare, points out that this treatment - which is not yet marketed - has the advantage, for HIV positive patients, of limiting the use of drugs to six times per year, against 365 today.
Copyright (c) 2020 CercleFinance.com. All rights reserved.